Median follow-up post-HBIG discontinuation was 40 (range, 5-51) months.
在停用HBIG后平均随访40个月（范围为5-51个月）。
HBIG was discontinued a median of 26 (range, 0.2-121) months after OLT.
在原位肝移植术后平均26(范围0.2 - 121个月)个月HBIG被停用。
Conclusion HBIG before laboring can decrease the HBV intrauterine infection rate.
结论产前应用hbig可降低HBV宫内感染率。
Probability of HBV recurrence was 0% and 9% at 2 and 4 years after HBIG discontinuation.
停用HBIG后第二年和第四年的乙肝复发概率分别为0%和9%。
CONCLUSIONS: The HBV intrauterine infection could be decreased by using HBIG during pregnancy.
结论：产前应用hbig可降低乙肝病毒宫内感染率。
RESULTS: Between February 1996 and October 2004, 147 patients received low-dose HBIG plus lamivudine.
结果：在1996年2月到2004年10月间，共有147名或者接受了低剂量hbig合用拉米夫定疗法。
Posttransplantation, all patients received lamivudine 100 mg daily plus IM HBIG 400 or 800 IU daily for 1 week then monthly thereafter.
移植后，所用患者均接受每日100mg拉米夫定另加每日肌注hbig400或800iu为期一周的治疗，随后该治疗每月进行一次。
Objective to investigate the effect of passive immunization of fetus by injection of HBIG to mothers for prevention of HBV intrauterine infection.
目的探讨经母亲对胎儿行被动免疫在预防乙型肝炎病毒(HBV)宫内感染中的作用。
AbstractObjectiveTo explore the effect on neonatal immunization with hepatitis B gene vaccine by interrupting HBV infection in pregnant women with HBIG 200IU.
目的探讨采用乙型肝炎免疫球蛋白（HBIG）阻断孕妇乙型肝炎病毒（HBV）感染对新生儿乙型肝炎（简称乙肝）基因疫苗免疫效果的影响。
AbstractObjectiveTo explore the effect on neonatal immunization with hepatitis B gene vaccine by interrupting HBV infection in pregnant women with HBIG 200IU.
目的探讨采用乙型肝炎免疫球蛋白（HBIG）阻断孕妇乙型肝炎病毒（HBV）感染对新生儿乙型肝炎（简称乙肝）基因疫苗免疫效果的影响。
应用推荐